This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2021 Jul;32(13-14):639-641.

doi: 10.1089/hum.2021.29167.syc.

Ocular Inflammation with Anti-Vascular Endothelial Growth Factor Treatments

Shun-Yun Cheng¹, Claudio Punzo¹

Affiliations

PMID: 34283642
DOI: 10.1089/hum.2021.29167.syc

Editorial

Ocular Inflammation with Anti-Vascular Endothelial Growth Factor Treatments

Shun-Yun Cheng et al. Hum Gene Ther. 2021 Jul.

. 2021 Jul;32(13-14):639-641.

doi: 10.1089/hum.2021.29167.syc.

Authors

Shun-Yun Cheng¹, Claudio Punzo¹

Affiliation

¹ Department of Ophthalmology, Gene Therapy Center, Neurobiology, University of Massachusetts Medical School, Worcester, Massachusetts, USA.

PMID: 34283642
DOI: 10.1089/hum.2021.29167.syc

No abstract available

PubMed Disclaimer

Similar articles

Vascular endothelial growth factor biology: clinical implications for ocular treatments.
Bhisitkul RB. Bhisitkul RB. Br J Ophthalmol. 2006 Dec;90(12):1542-7. doi: 10.1136/bjo.2006.098426. Br J Ophthalmol. 2006. PMID: 17114590 Free PMC article. Review.
[VEGF, anti-vEGF and diseases].
Corvol P. Corvol P. Bull Acad Natl Med. 2008 Feb;192(2):289-300; discussion 300-2. Bull Acad Natl Med. 2008. PMID: 18819684 Review. French.
Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases.
Kaiser PK. Kaiser PK. Am J Ophthalmol. 2006 Oct;142(4):660-8. doi: 10.1016/j.ajo.2006.05.061. Am J Ophthalmol. 2006. PMID: 17011860
Use of anti-vascular endothelial growth factor in the management of pterygium.
Mak RK, Chan TC, Marcet MM, Choy BN, Shum JW, Shih KC, Wong IY, Ng AL. Mak RK, et al. Acta Ophthalmol. 2017 Feb;95(1):20-27. doi: 10.1111/aos.13178. Epub 2016 Jul 30. Acta Ophthalmol. 2017. PMID: 27473792 Review.
Anti-Vegf Therapy for Ocular Diseases: Present and Future.
Campa C, Parodi MB. Campa C, et al. Curr Drug Targets. 2020;21(12):1158. doi: 10.2174/138945012112200727153907. Curr Drug Targets. 2020. PMID: 32957867 No abstract available.

See all similar articles

Cited by

Update on Viral Gene Therapy Clinical Trials for Retinal Diseases.
Cheng SY, Punzo C. Cheng SY, et al. Hum Gene Ther. 2022 Sep;33(17-18):865-878. doi: 10.1089/hum.2022.159. Hum Gene Ther. 2022. PMID: 36074935 Free PMC article. Review.
Immunogenicity of Novel AAV Capsids for Retinal Gene Therapy.
Gehrke M, Diedrichs-Möhring M, Bogedein J, Büning H, Michalakis S, Wildner G. Gehrke M, et al. Cells. 2022 Jun 9;11(12):1881. doi: 10.3390/cells11121881. Cells. 2022. PMID: 35741009 Free PMC article.
Recombinant adeno-associated virus as a delivery platform for ocular gene therapy: A comprehensive review.
Wang JH, Zhan W, Gallagher TL, Gao G. Wang JH, et al. Mol Ther. 2024 Dec 4;32(12):4185-4207. doi: 10.1016/j.ymthe.2024.10.017. Epub 2024 Oct 28. Mol Ther. 2024. PMID: 39489915 Review.
Adeno-Associated Virus Vectors in Retinal Gene Therapy: Challenges, Innovations, and Future Directions.
Huang J, Li J, Xu X, Li K. Huang J, et al. Biomolecules. 2025 Jun 28;15(7):940. doi: 10.3390/biom15070940. Biomolecules. 2025. PMID: 40723812 Free PMC article. Review.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon